The Food and Drug Administration, Office of Prescription Drug Promotion, has issued two new draft guides that illustrate the administration’s current approach to the use of the Internet and social media to promote drugs, according to Ginny Boland, assistant vice president of strategic communications at McGuire Woods, in a post on the FDA Life blog.
The “Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Presecription Drugs and Medical Devices” guide speaks to situations when pharmaceutical companies, drug makers and medical device manufacturers respond to a third-party’s communication that contains drug misinformation. The response should be, among other things, “non-promotional, accurate, relevant and responsive to the misinformation.” It also must be posted alongside the misinformation in the same forum.
